EL7.AI
StocksMedium•13 November 2026•
2 min read

Annovis Bio Reports $0.22 Per-Share Loss in Third Quarter as Research Spending Rises

Key Facts

1Basic and diluted net loss was $0.22 per share in the third quarter of 2026, compared with $0.37 a year earlier.
2Research and development expenses rose to $15.8 million, from $6.3 million in the third quarter of 2025.
3Cash and cash equivalents totaled $2.8 million on September 30, 2026, compared with $19.5 million on December 31, 2025.
4Enrollment of 850 patients in the Phase 3 trial was completed, exceeding the original target of 760 patients.
5The company expects a symptomatic-effects readout in the first quarter of 2027 and a disease-modifying-effects readout in the first quarter of 2028.

Annovis Bio reported on November 13 results for the third quarter ended September 30, 2026, posting basic and diluted net loss of $0.22 per share, according to the company. The loss was $0.37 per share in the year-earlier quarter. The per-share loss narrowed as research and development spending increased during the period. Research and development expenses were $15.8 million, compared with $6.3 million a year earlier. The company also recorded general and administrative expenses of $1.2 million, versus $1.1 million in the third quarter of 2025.

A comparison with the second quarter of 2026 shows research and development expenses continuing to rise, reaching $12.0 million, compared with $5.2 million in the same period of 2025. The company reported basic and diluted loss of $0.40 per share that quarter, compared with $0.32 a year earlier. At the end of September, Annovis had $2.8 million in cash and cash equivalents. The balance was $19.5 million on December 31, 2025. The company closed a $21 million public offering during November, with its chairman contributing 24% of the offering’s value.

ANVS shares closed at $0.8472 on November 12, according to EL7 data. They had closed at $0.8533 on November 11, $0.8743 on November 10 and $0.9013 on November 9. The company announced in August that it had completed enrollment of 850 patients in its pivotal Phase 3 trial for Alzheimer’s disease. The number exceeded the original enrollment target of 760 patients. The program is testing buntanetap, an experimental oral treatment taken once daily that the company is developing for neurodegenerative diseases including Alzheimer’s and Parkinson’s.

The trial includes two prespecified readouts: a 6-month analysis of symptomatic effects and an 18-month analysis of disease-modifying effects. The company expects to announce preliminary results on symptomatic effects after 6 months in the first quarter of 2027. It expects to announce results on disease-modifying effects after 18 months in the first quarter of 2028. The trial targets cognition and function as its two primary endpoints. These are the next two clinical milestones the company has announced for its program.

Open on chart